Huang, Yi

PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

Zheng, B., Ren, T., Huang, Y., Sun, K., Wang, S., Bao, X., Liu, K., & Guo, W. (2018) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment

Cited by 151

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Xie, L., Xu, J., Sun, X., Guo, W., Gu, J., Liu, K., Zheng, B., Ren, T., Huang, Y., Tang, X., et al. (2020) · Journal for ImmunoTherapy of Cancer

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 145

The role of tumor-associated macrophages in osteosarcoma progression – therapeutic implications

Huang, Q., Liang, X., Ren, T., Huang, Y., Zhang, H., Yu, Y., Chen, C., Wang, W., Niu, J., Lou, J., et al. (2021) · Cellular Oncology

Immune cells in cancerSarcoma Diagnosis and Treatment

Cited by 118

Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3

Zheng, B., Ren, T., Huang, Y., & Guo, W. (2018) · Biochemical and Biophysical Research Communications

Sarcoma Diagnosis and TreatmentAngiogenesis and VEGF in Cancer

Cited by 89